Jupiter Life Line Hospitals Ltd
Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India.[1]
- Market Cap ₹ 10,242 Cr.
- Current Price ₹ 1,562
- High / Low ₹ 1,654 / 1,037
- Stock P/E 58.6
- Book Value ₹ 203
- Dividend Yield 0.06 %
- ROCE 22.2 %
- ROE 17.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 53.0% CAGR over last 5 years
Cons
- Stock is trading at 7.71 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of Nifty Total Market BSE Healthcare BSE SmallCap Nifty Microcap 250 BSE Allcap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 320 | 398 | 463 | 461 | 657 | 787 | 911 | 988 | |
| 266 | 333 | 380 | 392 | 498 | 583 | 687 | 750 | |
| Operating Profit | 54 | 65 | 83 | 69 | 159 | 204 | 223 | 239 |
| OPM % | 17% | 16% | 18% | 15% | 24% | 26% | 25% | 24% |
| 5 | 2 | 2 | 4 | 4 | 11 | 30 | 36 | |
| Interest | 16 | 24 | 26 | 28 | 29 | 28 | 19 | 4 |
| Depreciation | 20 | 24 | 26 | 27 | 28 | 29 | 31 | 34 |
| Profit before tax | 24 | 20 | 33 | 18 | 106 | 159 | 204 | 237 |
| Tax % | -25% | 8% | 10% | 5% | 20% | 33% | 25% | |
| 30 | 18 | 30 | 17 | 85 | 107 | 152 | 176 | |
| EPS in Rs | 5.88 | 3.57 | 5.83 | 3.26 | 16.65 | 18.97 | 23.18 | 26.89 |
| Dividend Payout % | 8% | 0% | 0% | 0% | 0% | 0% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 25% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 53% |
| 3 Years: | 109% |
| TTM: | 69% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 46% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 22% |
| Last Year: | 18% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 51 | 51 | 51 | 51 | 57 | 66 | 66 |
| Reserves | 147 | 162 | 186 | 202 | 278 | 409 | 1,180 | 1,264 |
| 210 | 252 | 263 | 262 | 322 | 298 | 0 | 0 | |
| 63 | 71 | 94 | 100 | 104 | 123 | 115 | 135 | |
| Total Liabilities | 470 | 537 | 594 | 615 | 755 | 885 | 1,361 | 1,465 |
| 379 | 431 | 435 | 426 | 465 | 476 | 477 | 508 | |
| CWIP | 28 | 12 | 10 | 13 | 14 | 16 | 61 | 116 |
| Investments | 1 | 2 | 2 | 65 | 71 | 95 | 111 | 177 |
| 63 | 92 | 146 | 109 | 205 | 297 | 711 | 664 | |
| Total Assets | 470 | 537 | 594 | 615 | 755 | 885 | 1,361 | 1,465 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| 43 | 46 | 75 | 113 | 142 | 184 | 110 | |
| -43 | -58 | -43 | -78 | -68 | -130 | -256 | |
| 1 | 16 | -32 | -23 | 10 | -23 | 311 | |
| Net Cash Flow | 1 | 3 | -1 | 12 | 84 | 31 | 164 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 24 | 35 | 16 | 15 | 19 | 19 |
| Inventory Days | 60 | 46 | 64 | 45 | 38 | 42 | 39 |
| Days Payable | 224 | 168 | 268 | 192 | 155 | 169 | 116 |
| Cash Conversion Cycle | -144 | -98 | -169 | -132 | -101 | -108 | -59 |
| Working Capital Days | 11 | 18 | 44 | 4 | -4 | -16 | -7 |
| ROCE % | 10% | 12% | 9% | 23% | 27% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Nov - Reg 30 of the SEBI (LODR) Regulations, 2015, please find enclosed the transcript of the Q2 & H1 FY25 Results Conference Call held on Monday, …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
14 Nov - Schedule of Analyst/Investor meetings on November 22, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Schedule of Analyst/Investor meetings on November 18, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Nov - Audio link of Q2 & H1 FY 25 conference call.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Nov - Read with SEBI (LODR) Regulations, 2015, please find attached a copy of newspaper publication in the following newspapers with respect to Unaudited Financial Results (Standalone …
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptNotesPPT
Hospital Portfolio[1]
1. Locations and Bed Capacity
- Thane: Operational since 2007, 377 beds, average occupancy rate of 72.0%, and ARPOB (Average Revenue Per Occupied Bed) of ₹66,700.
- Pune: Operational since 2017, 375 beds, average occupancy rate of 67.0%, and ARPOB of ₹55,000.
- Indore: Operational since 2020, 231 beds, average occupancy rate of 59.0%, and ARPOB of ₹44,700.
New Developments[2]
- Added 22 beds in Pune in Q2 FY25.
- 75 additional beds are under development at the Indore hospital, expected by Q4 FY25.
- Construction of the Dombivli hospital is on track, and regulatory approvals are being finalized for a second unit in Pune. These expansions will raise the total bed capacity to ~2,500 beds.
Capex[3]
1) CWIP grew from 74 Crs in March 2024 to 135.1 Crs in September 2024, reflecting ongoing expansion projects.
2) The company spent 165.3 Crs on investments during H1 FY25.
Key Operating Metrics - H1FY25[4]
- Operational Beds: 851 beds.
- Occupancy Rate: 67.2%
- Patient Volume: Grew from 53,100 to 57,700.
- ALOS (Average Length of Stay): Slightly decreased to 3.85 days from 3.89 days.